The executive director of the Biosimilars Forum calls for policies to support adoption of lower-cost biologics.
Eight in 10 Americans say prescription drug costs are unreasonably high. Biosimilars are critical to decreasing these costs. Biosimilars are effective, lower-cost treatments that could alleviate the drug cost burden for millions of Americans. Policymakers and regulators should prioritize biosimilars to help patients achieve the full cost-saving potential of these treatments.
Biosimilars are FDA-approved, lower-cost biologic medicines that have the same safety and efficacy as their reference counterparts. Biosimilars are used to treat many chronic, life-threatening conditions, including cancer, diabetes, Crohn disease, arthritis, macular degeneration, and more. The approval pathway for biosimilars was established by the 2010 Biologics Price Competition and Innovation Act (BPCIA), within the Affordable Care Act (ACA), leading to the first biosimilar Zarxio approved in 2015 in the United States.
Biosimilars are projected to reduce drug costs by $133 billion in the United States by 2025. In addition to being a lower-cost treatment to brand biologics, biosimilars also lower the cost of other biologics. In fact, a 2021 study found the average price of brand biologics was estimated to be 56% higher without biosimilar competition—and up to 150% higher for some cases. For example, the average sales price (ASP) of the brand biologic Remicade was projected to be 150% higher in the absence of biosimilars, but the competition from biosimilars Inflectra, Renflexis, and Avsola lowered Remicade’s price. In total, biosimilars make up only about 20% share of the accessible biologic market. As this market share increases, so will the cost-savings for patients, providers, and payers.
Policies supporting the adoption of biosimilars are necessary to achieve the full cost savings these treatments can provide. For example, officials should reduce or eliminate out-of-pocket costs for Medicare Part B patients taking a biosimilar through a zero-co-pay policy. This policy would lower costs for patients and has widespread support among patient groups. In fact, more than a dozen US patient groups signed onto a letter to federal health care officials supporting a zero copay policy last year.
Another policy that has proven to support biosimilar adoption in the US and Europe is a shared savings model, which has been particularly successful in the oncology market. In a shared savings model, the savings gained from adopting lower cost biosimilars are shared with the provider and the patient. The Forum recommends policy makers expand the use of shared savings programs to additional therapeutic areas that have biosimilars, ophthalmology, inflammatory diseases, diabetes and other conditions.
Physicians and providers can also be supported through an increased add-on payment for a lower-cost biosimilar. Specifically, increasing the incentive from ASP+6% of the biosimilar to ASP+8% for a period of 5 years would help increase adoption. Twenty-eight health care groups - both patient and provider organizations-signed a letter to US Reps. Schrader and Kinzinger last year supporting this bipartisan policy initiative.
The continued slow market growth for US biosimilars increases the need for federal action, as the cost savings from biosimilars can support patient access and lower drug costs. Biosimilars can also help open the door for the future’s new and innovative treatments. Policymakers and regulators must prioritize biosimilars and create policies that increase their adoption.
Author Information
Juliana M. Reed is the executive director of the Biosimilars Forum. Prior to serving as executive director, Reed served as the Biosimilars Forum president for more than eight years and was one of its original co-founders. Email: juliana@biosimilarsforum.org
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.